Article

Cavin-2 Deficiency Attenuates Cardiac Fibrosis and Dysfunction in Pressure-overloaded Hearts

Register or Login to View PDF Permissions
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
Average (ratings)
No ratings
Your rating
Copyright Statement:

The copyright in this work belongs to Radcliffe Medical Media. Only articles clearly marked with the CC BY-NC logo are published with the Creative Commons by Attribution Licence. The CC BY-NC option was not available for Radcliffe journals before 1 January 2019. Articles marked ‘Open Access’ but not marked ‘CC BY-NC’ are made freely accessible at the time of publication but are subject to standard copyright law regarding reproduction and distribution. Permission is required for reuse of this content.

Best Abstract Award – First prize
Topic: Heart Failure (Basic), Molecular Cardiology

Introduction

Heart failure (HF) is a debilitating disease associated with high morbidity and mortality. The high mortality rate reflects inadequacy of modern therapy and calls for new mechanistic treatments. A major cause of HF is the adverse tissue remodelling with fibrosis. Excessive extracellular matrix (ECM) turnover is involved in poor outcome. Trans-differentiation of fibroblasts into activated myofibroblasts is a defining feature of fibrosis. Myofibroblasts express alpha-smooth muscle actin and secrete ECM proteins. Previous report showed that the cavin family gene is involved in cardiac function. However, the role of Cavin-2 in cardiac fibrosis and cardiac function remains unknown.

Methods and Results

To examine the role of Cavin-2 in cardiac function, transverse aortic constriction (TAC) was performed on wild type (WT) mice and Cavin-2-/- mice. Four weeks after TAC procedure, left ventricular fractional shortening was significantly preserved in Cavin-2-/- mice. In addition, the fibrosis area was significantly attenuated in Cavin-2-/- mice. Moreover, mRNA expression of fibrosis genes was attenuated in the hearts of Cavin-2-/- mice four weeks after TAC. In in vitro study, we isolated mouse embryonic fibroblasts (MEFs) from Cavin-2-/- mice and WT mice. Western blotting showed that alpha-smooth muscle actin protein level was decreased in TGF-alpha-1 stimulated MEFs derived from Cavin-2-/- mice. Furthermore, mRNA expression of fibrosis genes was attenuated in MEFs derived from Cavin-2-/- mice.

Conclusions

Our observations suggest that Cavin-2 contributes to the development of cardiac fibrosis and systolic dysfunction with the differentiation of fibroblasts into myofibroblasts. Cavin-2 may be a novel therapeutic target for cardiac fibrosis.